Published in Clin Cancer Res on August 01, 2003
DNA hypomethylation in cancer cells. Epigenomics (2009) 3.71
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One (2010) 1.65
DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer (2008) 1.60
MSRE-PCR for analysis of gene-specific DNA methylation. Nucleic Acids Res (2005) 1.21
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One (2008) 1.12
Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res (2003) 1.11
Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol (2007) 1.06
Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia (2007) 1.01
Epigenetic biomarkers in esophageal cancer. Cancer Lett (2012) 1.01
The epigenetic landscape of oral squamous cell carcinoma. Br J Cancer (2013) 1.01
Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia (2008) 1.00
Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol (2010) 0.98
Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer (2011) 0.96
Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform. Nucleic Acids Res (2006) 0.92
Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol (2012) 0.92
Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. J Transl Med (2009) 0.91
Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett (2008) 0.89
Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr Relat Cancer (2016) 0.88
Methylation-mediated gene silencing as biomarkers of gastric cancer: a review. World J Gastroenterol (2014) 0.88
Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol (2006) 0.88
Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol (2008) 0.87
Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol (2009) 0.86
Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol (2009) 0.85
CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol (2011) 0.85
Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark (2010) 0.83
The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. Clin Epigenetics (2016) 0.81
p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. J Clin Pathol (2007) 0.81
Methylation in esophageal carcinogenesis. World J Gastroenterol (2006) 0.80
Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview. Cancer Biol Med (2014) 0.79
Molecular changes in the progression of Barrett's oesophagus. Postgrad Med J (2007) 0.78
A novel method to quantify local CpG methylation density by regional methylation elongation assay on microarray. BMC Genomics (2008) 0.78
Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am (2015) 0.78
Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol (2014) 0.78
GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers? Gastroenterol Res Pract (2013) 0.77
Clinico-epigenetic combination including quantitative methylation value of DKK3 augments survival prediction of the patient with cervical cancer. J Cancer Res Clin Oncol (2012) 0.77
Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis (2016) 0.76
Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel. Genes Cancer (2015) 0.76
Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis. Oncotarget (2016) 0.75
Correlation of DAPK1 methylation and the risk of gastrointestinal cancer: A systematic review and meta-analysis. PLoS One (2017) 0.75
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med (2004) 9.55
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 6.82
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol (2013) 4.55
Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol (2004) 4.46
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol (2005) 4.16
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66
Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc (2012) 3.60
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc (2009) 3.46
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res (2006) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 2.83
Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med (2003) 2.80
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res (2005) 2.67
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle (2007) 2.55
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer (2005) 2.49
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol (2004) 2.41
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc (2008) 2.39
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Lymphocytic duodenosis and the spectrum of celiac disease. Am J Gastroenterol (2009) 2.26
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst (2009) 2.22
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol (2010) 2.18
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res (2008) 2.16
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.12
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
A novel 6C assay uncovers Polycomb-mediated higher order chromatin conformations. Genome Res (2008) 2.10
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction. Nat Mater (2008) 2.05
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res (2003) 2.04
Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res (2003) 2.03